0001144204-19-045298.txt : 20190919
0001144204-19-045298.hdr.sgml : 20190919
20190919191221
ACCESSION NUMBER: 0001144204-19-045298
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190917
FILED AS OF DATE: 20190919
DATE AS OF CHANGE: 20190919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lewis-Hall Freda C
CENTRAL INDEX KEY: 0001437909
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191102465
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
tv529791_form4.xml
FORM 4
X0306
4
2019-09-17
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001437909
Lewis-Hall Freda C
C/O SPRINGWORKS THERAPEUTICS, INC.
100 WASHINGTON BLVD.
STAMFORD
CT
06902
1
0
1
0
Common Stock
2019-09-17
4
C
0
978194
A
978194
I
By: Pfizer Inc.
Common Stock
2019-09-17
4
C
0
3039051
A
4017245
I
By: Pfizer Inc.
Common Stock
2019-09-17
4
C
0
526602
A
4543847
I
By: Pfizer Ventures (US) LLC
Common Stock
2019-09-17
4
P
0
50000
18
A
4593847
I
By: Pfizer Ventures (US) LLC
Junior Series A Convertible Preferred Stock
2019-09-17
4
C
0
978194
D
Common Stock
978194
0
I
By: Pfizer Inc.
Series A Convertible Preferred Stock
2019-09-17
4
C
0
3039051
D
Common Stock
3039051
0
I
By: Pfizer Inc.
Series B Convertible Preferred Stock
2019-09-17
4
C
0
526602
D
Common Stock
526602
0
I
By: Pfizer Ventures (US) LLC
Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date.
Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
Shares held by Pfizer Inc. ("Pfizer"). The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares.
Shares held by Pfizer Ventures. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures and disclaims beneficial ownership of all such shares.
/s/ Michael V. Greco, Attorney-in-Fact
2019-09-19